Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: luckydog88	7/18/2025 10:26:19 AM
	of 63320

BRIEF-Sarepta Says 51-Year-Old Male Patient Died In Early Stage Study Of SRP-9004 REUTERS Jul-18-2025 10:17 a.m. ET July 18 (Reuters) - Sarepta Therapeutics Inc (SRPT): * SAREPTA THERAPEUTICS SAYS 51-YEAR-OLD MALE PATIENT DIED IN AN EARLY STAGE STUDY OF CO'S THERAPY SRP-9004 - STATEMENT * SAREPTA THERAPEUTICS SAYS PATIENT WAS THE LAST TO BE DOSED IN THE STUDY, AND DIED OF ACUTE LIVER FAILURE * SAREPTA THERAPEUTICS SAYS PRIORITIZED DISCLOSING TRIAL PATIENT DEATH TO CLINICIANS, REGULATORS IN ACCORDANCE WITH TRIAL GUIDELINES * SAREPTA THERAPEUTICS SAYS ACUTE LIVER FAILURE IS NOT A NEW SAFETY SIGNAL, OCCURRED IN A TRIAL FOR A PROGRAM THAT CO IS NOT MOVING FORWARD WITH

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next